Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Lol
MRNA/PFE serious side effects
https://finance.yahoo.com/m/c68c9c6a-5c5a-351f-9c44-b3f51bcfff43/report-moderna-and-pfizer.html
WH discloses Trump received treatment with $REGN antibody cocktail
I don’t own shares but why would they do this? Won’t it really hurt current US holders at least in the short term?
Ryoncil BLA was under priority review with a 9 to 1 in favor adcomm.
MESO FDA recommended that Mesoblast conduct at least one additional randomized, controlled study in adults and/or children to provide further evidence of the effectiveness of remestemcel-L for SR-aGVHD.
$ETON Announces FDA Approval of Orphan Drug ALKINDI SPRINKLE as Replacement Therapy in Pediatric Patients with Adrenocortical Insufficiency
Ceo to be on Bloomberg Monday after the close
https://www.bloomberg.com/series/bloomberg-technology
SGEN/MRK announce deal
https://finance.yahoo.com/news/seattle-genetics-merck-announce-two-104500702.html
Exciting board.
Oxford University to Resume U.K. Trial of AstraZeneca Vaccine
TRIL prices $130m offering at $13.00/share
BYSI Receives Breakthrough Therapy Designations from Both U.S. FDA and China NMPA for Plinabulin in Chemotherapy-Induced Neutropenia Indication
Fail CRBP Announces Topline Results from RESOLVE-1 Phase 3 Study of Lenabasum for Treatment of Systemic Sclerosis. #Fail
ALBO positive results
http://ir.albireopharma.com/static-files/d3df0f8f-336f-45eb-b6df-2d08e5e99596
ALBO Albireo to Announce Topline Results from PEDFIC 1 Phase 3 Trial of Odevixibat on September 8, 2020
Conference call and webcast to be held at 8:30 a.m. EDT
Gilead Sciences and Jounce Therapeutics Announce Exclusive License Agreement for Novel Immunotherapy Program
– Gilead to Make $85 Million Upfront Payment and $35 Million Equity Investment
SRPT Announces FDA Acceptance of Casimersen (SRP-4045) New Drug Application for Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 45. I believe priority review too
PDUFA February 25, 2021
Expecting a PR tomorrow from SRNE about them having an advanced plasma Tx ready for approval
very interesting play. just bought in. impressive management
BMRN Receives CRL for Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A
https://www.stocktitan.net/news/BMRN/bio-marin-receives-complete-response-letter-crl-from-fda-for-7o4finka8en1.html
GILD $GLPG Receives CRL for Filgotinib for the Treatment of Moderately to Severely Active Rheumatoid Arthritis
ceo says they are not going to use it unless they see opportunities to advance the company. i think it's a great idea imo to have it handy. they have no intention of flooding the market with the ATM
LGND to acquire PFNX
https://newsfilter.io/a/e9c72d4a1dd1ecca39eeee3bbda23900
Wow, anyone see RLFTF?